PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that the Company will initiate the third phase of its drug development program, with researchers undertaking important toxicity studies of several select, patented anti-cancer compounds shown to successfully kill cells associated with several difficult-to-treat human cancers.
